Financing Adaptogenic Mushroom Companies: Seven Basic Regulatory Points to Understand

By Charles Alovisetti, Joshua Kappel, Andrea Golan Dec 2, 2021     Aside from a small number of companies the FDA has permitted to pursue the development of psilocybin therapies (e.g., Compass), the majority of psychedelic mushroom sales in the U.S. currently violate both state and federal law. As we wait for federal legalization and/or state-regulated psilocybin […]


Go to Source

Powered by WPeMatico